New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - palivizumab 50mg (;+ overage = 73mg/vial) - injection with diluent - 50 mg - active: palivizumab 50mg (;+ overage = 73mg/vial) excipient: glycine histidine mannitol nitrogen water for injection - synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age < 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd).

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية حسام النمر - hussam al nmer drug store - palivizumab 50 mg - 50 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - palivizumab 50mg;   - solution for injection - 100 mg/ml - active: palivizumab 50mg   excipient: glycine histidine water for injection - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd).

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 50 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - palivizumab 50 mg/0.5 ml - 50 mg/0.5 ml

United States - English - NLM (National Library of Medicine)

medimmune, llc - palivizumab (unii: dq448mw7ks) (palivizumab - unii:dq448mw7ks) - palivizumab 100 mg in 1 ml - 1 indications and usage synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in pediatric patients: limitations of use: the safety and efficacy of synagis have not been established for treatment of rsv disease [see warnings and precautions (5.4)] . synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to synagis [see warnings and precautions (5.1)] . risk summary synagis is not indicated for use in females of reproductive potential. risk summary synagis is not indicated for use in females of reproductive potential. the safety and effectiveness of synagis in children older than 24 months of age at the start of dosing have not been established [see clinical studies (14) ] .

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 100 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

Canada - English - Health Canada

abbvie corporation - palivizumab - powder for solution - 50mg - palivizumab 50mg - monoclonal antibodies

Canada - English - Health Canada

astrazeneca canada inc - palivizumab - solution - 50mg - palivizumab 50mg - monoclonal antibodies

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - palivizumab - solution for injection - 100mg/1ml